NGM Announces Change to Virtual Format for 2020 Annual Meeting of Stockholders
May 08 2020 - 4:05PM
NGM Biopharmaceuticals, Inc. (Nasdaq: NGM) today announced
that, due to public health and safety concerns related to the
coronavirus (COVID-19) pandemic, recommendations and orders from
federal, state and local authorities, and to support the health and
well-being of its stockholders, employees, and others, it will host
its 2020 Annual Meeting of Stockholders (“Annual Meeting”) as a
virtual-only meeting that will be held via live audio webcast. The
virtual Annual Meeting is expected to provide stockholders with the
same rights and opportunities to participate as they would have at
an in-person meeting.
The previously announced date and time of the Annual Meeting,
Wednesday, May 20, 2020 at 7:30 a.m. Pacific Daylight Time, as
disclosed in the previously distributed Notice of the Annual
Meeting and Definitive Proxy Statement (the “Notice and Proxy
Statement”), has not changed. Online access to the Annual Meeting
will begin at 6:30 a.m. Pacific Daylight Time. Stockholders will
not be able to attend the Annual Meeting in person.
Attending the Virtual Meeting
Stockholder of Record: Shares Registered in Your NameNGM's
stockholders of record as of the close of business on March 23,
2020 (the “Record Date”) can attend the Annual Meeting by
accessing the meeting center at https://web.lumiagm.com/219866537
and entering the control number on the proxy card or Notice of
Internet Availability of Proxy Materials previously received and
entering the meeting password ngm2020 (the password is case
sensitive). Instructions on how to connect to the Annual Meeting
and participate via the Internet, including how to demonstrate
proof of stock ownership, are also available at the meeting
website.
If you do not have your control number, you will be able to
access and listen to the Annual Meeting, but you will not be able
to vote your shares. See caption below titled “Attending the Annual
Meeting as a Guest.”
The webcast of the Annual Meeting will be archived for one year
after the date of the Annual Meeting at
https://web.lumiagm.com/219866537.
Beneficial Owner: Shares Registered in the Name of Broker or
BankBeneficial owners as of the Record Date (i.e. shares held
in “street name” through an intermediary, such as a brokerage firm,
bank, dealer or other similar organization), who want to attend the
Annual Meeting must register in advance to attend the virtual
meeting. To register, obtain a legal proxy from the bank, broker or
other nominee that is the record holder of your shares and then
submit the legal proxy, proof of your share ownership on the Record
Date, and your name and email address to American Stock Transfer
and Trust Company LLC to receive a control number that may be used
to access and vote your shares on the virtual meeting site. Any
control number that was previously provided with your proxy
materials will not provide access to the virtual meeting site.
Requests for registration should be labeled as “Legal Proxy” and
must be received no later than 5:00 p.m., Eastern Time, on May 15,
2020. Submit your registration request and supporting documentation
by: (1) email to proxy@astfinancial.com; (2) facsimile to
718‑765‑8730, or (3) mail to American Stock Transfer & Trust
Company, LLC, Attn: Proxy Tabulation Department, 6201 15 Avenue,
Brooklyn, NY 11219. Obtaining a legal proxy may take
several days and you are advised to register as far in advance as
possible. Once you have obtained your control number
from American Stock Transfer and Trust Company, please follow the
steps set forth above for registered stockholders to attend the
virtual meeting.
Asking QuestionsIf you are attending the Annual
Meeting as stockholder of record or beneficial owner, questions can
be submitted by accessing the meeting center at
https://web.lumiagm.com/219866537 and entering your control number.
Instructions on how to participate in the Annual Meeting are
available on the meeting website.
Voting SharesStockholders of record and
beneficial owners will be able to vote their shares electronically
during the Annual Meeting by entering the Annual Meeting using the
control number. Instructions on how to vote while participating in
the Annual Meeting live via the Internet are posted at
https://web.lumiagm.com/219866537.
NGM encourages stockholders to vote and submit their
proxy in advance of the Annual Meeting by one of the methods
described in the proxy materials for the
Annual Meeting.
The proxy materials, including the proxy card and Notice of
Internet Availability of Proxy Materials, previously distributed
along with the Notice and Proxy Statement, will not be updated to
reflect the change in location and may continue to be used to vote
shares in connection with the Annual Meeting.
Attending the Annual Meeting as a GuestGuests
may enter the Annual Meeting in “listen-only” mode by entering the
Annual Meeting at https://web.lumiagm.com/219866537 and entering
the meeting password ngm2020 (the password is case sensitive).
Guests will not have the ability to vote or ask questions during
the Annual Meeting.
List of StockholdersA list of stockholders
entitled to vote at the Annual Meeting will be available for
examination for any purpose germane to the Annual Meeting for ten
days prior to the Annual Meeting. You may email NGM at
ir@ngmbio.com to coordinate arrangements to view the stockholder
list. The stockholder list will also be available during the Annual
Meeting at https://web.lumiagm.com/219866537. Instructions on how
stockholders of records can view the stockholder list during the
Annual Meeting are available on the meeting website.
About NGM Biopharmaceuticals, Inc.NGM is a
biopharmaceutical company focused on developing novel therapeutics
based on scientific understanding of key biological pathways
underlying cardio-metabolic, liver, oncologic and ophthalmic
diseases. We leverage our biology-centric drug discovery approach
to uncover novel mechanisms of action and generate proprietary
insights that enable it to move rapidly
into proof-of-concept studies and deliver
potential first-in-class medicines to patients. At NGM,
we aspire to operate one of the most productive research and
development engines in the biopharmaceutical industry, with
multiple programs in clinical development. Please visit us at
www.ngmbio.com for more information.
Investor
Contact: Sylvia Wheeler and Alexandra Santos
swheeler@wheelhouselsa.com asantos@wheelhouselsa.com
ir@ngmbio.com |
Media
Contact: Liz Melone media@ngmbio.com |
NGM Biopharmaceuticals (NASDAQ:NGM)
Historical Stock Chart
From Aug 2024 to Sep 2024
NGM Biopharmaceuticals (NASDAQ:NGM)
Historical Stock Chart
From Sep 2023 to Sep 2024